Paying for a Cure You Can Only Give Once: How Outcomes-Based and Annuity Agreements Work

A one-time gene therapy priced in the millions creates a payment problem that ordinary drug contracts were never built to solve. Managed entry agreements answer it by tying money to time and results. An outcomes-based agreement refunds part of the price if the promised benefit fades, an annuity or installment contract spreads a single payment across several years and can stop if the therapy stops working, and a warranty guarantees money back if a defined efficacy threshold is missed. All three exist because a cure given once cannot be stopped, returned, or re-dosed, yet no one can prove at the point of sale how long its benefit will last.

Why a one-time cure breaks the usual payment logic

Chronic medicines are paid for as they are used. If a daily drug fails, prescribing simply stops, and spending stops with it. A durable gene therapy inverts this. The full clinical bet, and often the full cost, lands on a single infusion, while the evidence of lasting benefit accrues over years the payer cannot see in advance.

Two uncertainties sit at the center. The first is durability, meaning whether the effect measured in a short trial persists for a decade or erodes. The second is measurement, meaning whether real-world data can actually confirm that persistence in a way both sides accept. A systematic review of managed entry agreements for advanced therapy medicinal products, published in Clinical Therapeutics, catalogs these barriers, describing high launch prices set against limited clinical evidence from short-term, single-arm studies in small populations as the recurring difficulty these contracts try to manage.

Outcomes-based agreements: paying for results over time

An outcomes-based agreement ties payment to whether a patient actually achieves a pre-specified health result over a set window. If the therapy underperforms against that benchmark, the manufacturer returns some agreed portion of what was paid. The mechanism converts an unverifiable promise into a conditional transaction.

The clearest current example is public. In its Cell and Gene Therapy Access Model, the Centers for Medicare and Medicaid Services negotiated the key terms of outcomes-based agreements on behalf of states with the manufacturers of the two approved sickle cell disease gene therapies. As the U.S. Department of Health and Human Services described the model, payment is linked to whether patients achieve improved health outcomes over time, and a manufacturer provides a rebate if a therapy does not deliver as agreed. CMS reported that 33 states, plus the District of Columbia and Puerto Rico, agreed to participate, representing roughly 84 percent of Medicaid beneficiaries with the condition.

The design's hard part is not the rebate formula. It is defining an outcome that is clinically meaningful, attributable to the therapy, and trackable across payers and years.

Annuity and installment models: spreading the payment across time

Annuity or installment agreements address affordability directly by unbundling one enormous charge into a stream of smaller ones. Instead of a single seven-figure payment, the payer pays across several years. When the installments are also made contingent on continued benefit, the annuity doubles as a durability hedge, because payments can be reduced or halted if the patient loses response.

The logic is that a payer can absorb a large cost that arrives in scheduled pieces far more easily than the same cost demanded at once, and that linking those pieces to sustained performance keeps a manufacturer accountable after the infusion. Health-policy analyses have proposed annuity payments, often paired with an outcomes-based scheme, as one response to the budget-impact shock these therapies create, while noting conditions that make them workable, such as an excessive budget impact, rough cost equivalence with an upfront payment, and a limited annuity period. In practice, the availability of pay-over-time terms varies by therapy and by payer.

Warranties: a defined promise against early failure

A warranty is the most familiar of the three because it borrows consumer logic. The manufacturer commits, up front, that if the therapy fails to meet a stated efficacy standard within a specified period, it will provide a refund or financial offset. It shifts the risk of early efficacy failure from the payer back toward the maker.

Warranty structures have appeared alongside newly approved one-time therapies as a way to give payers financial protection against the specific scenario of a treatment that does not hold. The value of a warranty rests entirely on how its trigger is written, meaning the threshold, the follow-up window, and who adjudicates whether the failure occurred.

The measurement problem that limits all three

Every one of these instruments depends on evidence that a therapy did or did not work, and here the record is sobering. A Belgian analysis of outcome-based managed entry agreements for rare disease therapies, presented as a 2025 conference abstract in the International Journal of Technology Assessment in Health Care, examined agreements for 57 orphan drugs reimbursed between 2012 and 2024. It found that real-world evidence was frequently rejected at reassessment because of concerns about data validity and incomplete registries. Only about 8 percent of those agreements resulted in a definitive listing decision, with a median duration near 24 months and some extended or renewed up to five times.

That finding is the practical caution behind the enthusiasm. A contract can specify an elegant refund the moment benefit is lost, but it only pays out if a registry actually captured the outcome, if the data survive scrutiny, and if both parties agree on what the numbers mean. Clearer data-collection protocols and greater transparency are really the precondition for every model above to function. Without trustworthy measurement, an outcomes-based agreement is a promise no one can enforce, an annuity cannot know when to pause, and a warranty cannot know when it has been triggered.

These agreements do not lower a therapy's price or resolve whether it works. They redistribute the durability and affordability risk between payer and manufacturer, and their credibility lives entirely in the quality of the evidence infrastructure underneath them. This article is educational and is not medical advice.